Cargando…
EGFR突变状态对Ⅲ期非鳞非小细胞肺癌患者放化疗近期疗效和长期生存的预测价值
BACKGROUND AND OBJECTIVE: The presence of epidermal growth factor receptor (EGFR) mutations is predictive of a better response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) and initial chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC). The aim of this study is to analyze the...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999609/ https://www.ncbi.nlm.nih.gov/pubmed/21924037 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.09.03 |
_version_ | 1783331450487046144 |
---|---|
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: The presence of epidermal growth factor receptor (EGFR) mutations is predictive of a better response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) and initial chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC). The aim of this study is to analyze the association between the EGFR mutations and the outcome of combined chemoradiotherapy in stage Ⅲ non-squamous NSCLC. METHODS: Patients with stage Ⅲ non-squamous NSCLC whose EGFR mutation status had been identified were retrospectively analyzed. The response of 87 patients to combined chemoradiotherapy, the two-year survival rate, and the response of 128 patients to initial chemotherapy were evaluated. RESULTS: The response rate to combined chemoradiotherapy was 84.6% (33/39) in EGFR mutation-positive patients, significantly higher than the 56.3% (27/48) response rate in EGFR mutation-negative patients (P=0.004). Two-year survival rates were 53.8% and 50% in EGFR mutation-positive and mutation-negative patients, respectively. There was no significant difference in the overall survival for both patient groups. The overall response rate to initial chemotherapy was 34.5% (19/55) in EGFR mutation-positive patients, compared with the 21.9% (16/73) response rate in EGFR mutation-negative patients. CONCLUSION: EGFR mutation-positive status can predict better response to combined chemoradiotherapy, but is not associated with overall survival in patients with stage Ⅲ non-squamous NSCLC. |
format | Online Article Text |
id | pubmed-5999609 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-59996092018-07-06 EGFR突变状态对Ⅲ期非鳞非小细胞肺癌患者放化疗近期疗效和长期生存的预测价值 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: The presence of epidermal growth factor receptor (EGFR) mutations is predictive of a better response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) and initial chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC). The aim of this study is to analyze the association between the EGFR mutations and the outcome of combined chemoradiotherapy in stage Ⅲ non-squamous NSCLC. METHODS: Patients with stage Ⅲ non-squamous NSCLC whose EGFR mutation status had been identified were retrospectively analyzed. The response of 87 patients to combined chemoradiotherapy, the two-year survival rate, and the response of 128 patients to initial chemotherapy were evaluated. RESULTS: The response rate to combined chemoradiotherapy was 84.6% (33/39) in EGFR mutation-positive patients, significantly higher than the 56.3% (27/48) response rate in EGFR mutation-negative patients (P=0.004). Two-year survival rates were 53.8% and 50% in EGFR mutation-positive and mutation-negative patients, respectively. There was no significant difference in the overall survival for both patient groups. The overall response rate to initial chemotherapy was 34.5% (19/55) in EGFR mutation-positive patients, compared with the 21.9% (16/73) response rate in EGFR mutation-negative patients. CONCLUSION: EGFR mutation-positive status can predict better response to combined chemoradiotherapy, but is not associated with overall survival in patients with stage Ⅲ non-squamous NSCLC. 中国肺癌杂志编辑部 2011-09-20 /pmc/articles/PMC5999609/ /pubmed/21924037 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.09.03 Text en 版权所有©《中国肺癌杂志》编辑部2011 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | 临床研究 EGFR突变状态对Ⅲ期非鳞非小细胞肺癌患者放化疗近期疗效和长期生存的预测价值 |
title | EGFR突变状态对Ⅲ期非鳞非小细胞肺癌患者放化疗近期疗效和长期生存的预测价值 |
title_full | EGFR突变状态对Ⅲ期非鳞非小细胞肺癌患者放化疗近期疗效和长期生存的预测价值 |
title_fullStr | EGFR突变状态对Ⅲ期非鳞非小细胞肺癌患者放化疗近期疗效和长期生存的预测价值 |
title_full_unstemmed | EGFR突变状态对Ⅲ期非鳞非小细胞肺癌患者放化疗近期疗效和长期生存的预测价值 |
title_short | EGFR突变状态对Ⅲ期非鳞非小细胞肺癌患者放化疗近期疗效和长期生存的预测价值 |
title_sort | egfr突变状态对ⅲ期非鳞非小细胞肺癌患者放化疗近期疗效和长期生存的预测价值 |
topic | 临床研究 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999609/ https://www.ncbi.nlm.nih.gov/pubmed/21924037 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.09.03 |
work_keys_str_mv | AT egfrtūbiànzhuàngtàiduìiiiqīfēilínfēixiǎoxìbāofèiáihuànzhěfànghuàliáojìnqīliáoxiàohézhǎngqīshēngcúndeyùcèjiàzhí AT egfrtūbiànzhuàngtàiduìiiiqīfēilínfēixiǎoxìbāofèiáihuànzhěfànghuàliáojìnqīliáoxiàohézhǎngqīshēngcúndeyùcèjiàzhí AT egfrtūbiànzhuàngtàiduìiiiqīfēilínfēixiǎoxìbāofèiáihuànzhěfànghuàliáojìnqīliáoxiàohézhǎngqīshēngcúndeyùcèjiàzhí AT egfrtūbiànzhuàngtàiduìiiiqīfēilínfēixiǎoxìbāofèiáihuànzhěfànghuàliáojìnqīliáoxiàohézhǎngqīshēngcúndeyùcèjiàzhí AT egfrtūbiànzhuàngtàiduìiiiqīfēilínfēixiǎoxìbāofèiáihuànzhěfànghuàliáojìnqīliáoxiàohézhǎngqīshēngcúndeyùcèjiàzhí AT egfrtūbiànzhuàngtàiduìiiiqīfēilínfēixiǎoxìbāofèiáihuànzhěfànghuàliáojìnqīliáoxiàohézhǎngqīshēngcúndeyùcèjiàzhí AT egfrtūbiànzhuàngtàiduìiiiqīfēilínfēixiǎoxìbāofèiáihuànzhěfànghuàliáojìnqīliáoxiàohézhǎngqīshēngcúndeyùcèjiàzhí AT egfrtūbiànzhuàngtàiduìiiiqīfēilínfēixiǎoxìbāofèiáihuànzhěfànghuàliáojìnqīliáoxiàohézhǎngqīshēngcúndeyùcèjiàzhí AT egfrtūbiànzhuàngtàiduìiiiqīfēilínfēixiǎoxìbāofèiáihuànzhěfànghuàliáojìnqīliáoxiàohézhǎngqīshēngcúndeyùcèjiàzhí |